Currently, anti-EGFR therapy is mainly used for treating metastatic colorectal cancer patients with wild-type RAS/BRAF, since RAS/BRAF mutant patients do not respond well to anti-EGFR therapy. The gene discussed is BRAF; the disease is metastatic colorectal cancer.